Tag Archives: Forest Laboratories
By Pharm Exec | Published: November 18, 2014
Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 — a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData.
By Pharm Exec | Published: February 19, 2014
Actavis and Forest Laboratories have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share, Actavis announced in a press release. The transaction will combine the two high-growth specialty pharmaceutical companies, with combined annual revenues of more […]
By admin | Published: July 19, 2011
Steven Blum, Director of Health Economics at Forest Laboratories and one of Pharm Exec’s 2011 Emerging Pharma leaders, recently spoke with Associate Editor Jennifer Ringler on building leadership and team rapport in today’s lean organization.
By Ben Comer | Published: April 15, 2011
Forest Laboratories’ CEO Howard Solomon was no doubt surprised to receive a form letter from the Office of Inspector General (OIG) on April 8, which, if acted upon, would exclude him from doing business with federal healthcare plans, including Medicare and Medicaid. Solomon has 30 days to explain to the OIG why he should not […]
By admin | Published: April 14, 2010
Image by noii’s via Flickr FDA, on Tuesday, announced that it would phase out the use of seven asthma and chronic obstructive pulmonary disease inhalers to keep in check with regulations banning devices containing chlorofluorocarbons (CFCs). Four of the devices have already been discontinued, and the manufacturers of the remaining devices will have to find […]